A detailed history of Bank Of America Corp transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 81,642 shares of ATXS stock, worth $787,845. This represents 0.0% of its overall portfolio holdings.

Number of Shares
81,642
Previous 129,943 37.17%
Holding current value
$787,845
Previous $1.18 Million 24.03%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$8.97 - $12.65 $433,259 - $611,007
-48,301 Reduced 37.17%
81,642 $898,000
Q2 2024

Aug 14, 2024

BUY
$8.83 - $13.51 $181,394 - $277,535
20,543 Added 18.78%
129,943 $1.18 Million
Q1 2024

May 15, 2024

BUY
$6.99 - $16.69 $380,507 - $908,536
54,436 Added 99.04%
109,400 $1.54 Million
Q4 2023

Feb 14, 2024

BUY
$4.42 - $8.06 $152,375 - $277,860
34,474 Added 168.25%
54,964 $422,000
Q2 2023

Aug 14, 2023

BUY
$8.33 - $13.72 $61,042 - $100,540
7,328 Added 55.68%
20,490 $170,000
Q1 2023

May 12, 2023

BUY
$11.2 - $15.79 $22,960 - $32,369
2,050 Added 18.45%
13,162 $175,000
Q4 2022

Feb 10, 2023

BUY
$7.44 - $14.89 $22,468 - $44,967
3,020 Added 37.32%
11,112 $165,000
Q3 2022

Nov 14, 2022

BUY
$2.97 - $10.34 $22,355 - $77,829
7,527 Added 1332.21%
8,092 $73,000
Q2 2022

Aug 12, 2022

BUY
$2.46 - $6.96 $1,353 - $3,828
550 Added 3666.67%
565 $1,000
Q1 2022

May 16, 2022

SELL
$3.92 - $7.1 $15,256 - $27,633
-3,892 Reduced 99.62%
15 $0
Q4 2021

Feb 08, 2022

BUY
$5.08 - $8.62 $13,360 - $22,670
2,630 Added 205.95%
3,907 $21,000
Q3 2021

Nov 15, 2021

BUY
$7.32 - $12.9 $9,347 - $16,473
1,277 New
1,277 $11,000

Others Institutions Holding ATXS

About Astria Therapeutics, Inc.


  • Ticker ATXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,178,000
  • Market Cap $146M
  • Description
  • Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...
More about ATXS
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.